ADVANTAN Presentation Uses - Medsafe

ADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.

  Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate

LOXALATE 1. Product Name - Medsafe Home Page

Page 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.

  Risks, Combination

DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …

New Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …

  Sheet, Data, Data sheet, Clexane

SEPTANEST Articaine hydrochloride 4% with …

SEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.

  Articaine

BOOSTRIX - Medsafe Home Page

1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.

  Information, Boostrix

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a

  Cymevene

Edition Draft - Medsafe

Part 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for

  Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice

Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …

New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …

  Product, Name, Sheet, Data, Data sheet 1 product name

NEW ZEALAND DATA SHEET MESTINON® - Medsafe

NEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to

  Myasthenia, Gravis, Myasthenia gravis, Mestinon

DATA SHEET PREDNISONE - Medsafe

• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since

  Myasthenia, Gravis, Myasthenia gravis, Prednisone

INJECTABLE MEDICATIONS FEE SCHEDULE ONCOLOGY …

code description max qty rate comments/notes injectable medications fee schedule oncology 01/01/2018 j9151 daunorubicin citrate, liposomal formulation

  Rates, Descriptions, Comments, Description max qty rate comments

ANAL CANCER - Jones & Bartlett Learning

1 A 5-Fluorouracil Mitomycin Radiation Therapy (Wayne State regimen).....2 5-Fluorouracil: 1000 mg/m2/day IV continuous infusion on days 1–4 and 29–32 Mitomycin: 15 mg/m2 IV on day 1 Radiation therapy: 200 cGy/day on days 1–5, 8–12, and 5–19 (total dose,

  Fluorouracil

OUR CLINICAL TRIALS - Amgen Oncology

*For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgentrials.com. †The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification.

FOR PHYSICIAN-ADMINISTERED PRODUCTS PATIENT …

PO Box 18769 Louisville, KY 40261-7821 Phone: (888) 762-6436 Fax: (866) 549-7239 www.safetynetfoundation.com

  Product, Patients, Physician, Administered, For physician administered products patient

BREAST CANCER TREATMENT REGIMENS (Part 1 of 6)

BREAST CANCER TREATMENT REGIMENS (Part 2 of 6) REGIMEN DOSING Adjuvant Therapy Without Concomitant Trastuzumab Tamoxifen1,8 Tamoxifen 20–40mg orally daily for no longer than 5 years (doses higher than 20mg should be divided into 2 doses, AM and PM).

  Treatment, Part, Breast, Cancer, Regimens, Breast cancer treatment regimens

HIGHLIGHTS OF PRESCRIBING INFORMATION NEULASTA …

3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Patients with CancerReceiving Myelosuppressive Chemotherapy Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with

Patient Information Single-Dose Prefilled Syringe

PatientInformation Neulasta®(nu-las-tah) (pegfilgrastim) injection On-body injector for Neulasta What is the most important information I need to know about receiving Neulasta with the on-body injector for

  Pegfilgrastim